Estrogen receptor alpha in human breast cancer: Occurrence and significance

Journal of Mammary Gland Biology and Neoplasia

Volumn 5, Issue 3, 2000, Pages 271-281

  Ali, Simak ^a   Coombes, R Charles ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Endocrine therapies; Estrogen receptor; Resistance

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FORMESTANE; FULVESTRANT; GOSERELIN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; VOROZOLE;

AROMATIZATION; BLOOD LEVEL; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST TUMOR; CANCER GROWTH; CANCER RISK; CELL PROLIFERATION; DRUG WITHDRAWAL; GENE MUTATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; LIGAND BINDING; NONHUMAN; PROGNOSIS; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; TUMOR RESISTANCE;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 0034485142     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009594727358     Document Type: Review

References (87)

1. Breast cancer epidemiology
2. Role of hormones in mammary cancer initiation and progression
3. Steroid receptor regulated transcription of specific genes and gene networks
4. The nuclear receptor superfamily: The second decade
5. Orphan nuclear receptors: New ligands and new possibilities
6. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements
7. Molecular basis of agonism and antagonism of the oestrogen receptor
8. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
9. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains
10. Transcription activation by estrogen and progesterone receptors
11. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
12. Steroid hormone receptors: Many actors in search of a plot
13. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
14. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
15. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein
16. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II)
17. Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor
18. p300 is a component of an estrogen receptor coactivator complex
19. Increasing the complexity of coactivation in nuclear receptor signaling
20. The coregulator exchange in transcriptional functions of nuclear receptors
21. Nuclear receptors in Sicily: All in the famiglia
22. The role of coactivators and corepresors in biology and mechanism of action of steroid hormone receptors
23. Molecular basis of agonism and antagonism of the oestrogen receptor
24. The nuclear receptor ligand-binding domain: Structure and function
25. Estrogen and progesterone receptors in the normal female breast
26. Estrogen receptor expression in benign breast epithelium and breast cancer risk
27. Breast carcinoma developing in patients on hormone replacement therapy: A histological and immunohistological study
28. Estrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle
29. Induction of renal tumors by estrogens
30. Molecular origin of cancer: Catechol estrogen-3, 4-quinones as endogenous tumor initiators
31. Synthesis and characterization of estrogen 2, 3- and 3, 4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens
32. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1
33. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility
34. Estrogen receptors and breast cancer
35. Hormone receptors and breast cancer
36. Endogenous estrogens and risk of breast cancer by estrogen receptor status: A prospective study in postmenopausal women
37. Estrogen receptor: A stable phenotype in breast cancer
38. Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone
39. 4-hydroxy-androstenedione: A new treatment for post-menopausal patients with breast cancer
40. Effects of endocrine therapy on steriod-receptor content of breast cancer
41. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
42. The effect of endocrine therapy on the levels of estrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: An immunocytochemical study
43. Polychemo-therapy for early breast cancer: An overview of the randomised trials
44. Prediction of endocrine response in breast cancer by immunocytochemical detection of estrogen receptor in fine needle aspirates
45. Estrogen receptor variants
46. Estrogen receptor gene structure and function in breast cancer
47. Estrogen receptors α and β in the rodent mammary gland
48. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor α
49. Estrogen receptor α and β form heterodimers on DNA
50. The complete primary structure of human estrogen receptor β (hERBβ) and its heterodimerization with ERα in vivo and in vitro
51. Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α
52. Presence of exon 5-deleted oestrogen receptor in human breast cancer: Functional analysis and clinical significance
53. The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1
54. The regulation of transcription by phosphorylation
55. Regulating transcription factor activity by phosphorylation
56. Signal transduction from the cell surface to the nucleus through phosphorylation of transcription factors
57. Cross-talk between peptide growth factor and estrogen receptor signaling pathways
58. Modulating nuclear receptor function: May the phos be with you
59. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein
60. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine
61. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer
62. Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation
63. Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization
64. Phosphorylation of the human oestrogen receptor. Identification of a phosphorylation site required for transactivation
65. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity
66. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167
67. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex
68. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
69. Activation of the unliganded estrogen receptor by EFG involves the MAP kinase pathway and direct phosphorylation
70. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase
71. Activation of estrogen receptor a by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7
72. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue
73. Cyclic AMP binding proteins and prognosis in breast cancer
74. Hyperexpression of mitogen-activated protein kinase in human breast cancer
75. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells
76. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3)
77. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
78. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene
79. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development
80. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
81. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer
82. The influence of CGS 16949A on peripheral aromatization in breast cancer patients
83. Vorozole results in greater estrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
84. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilized on formestane therapy
85. Aromatase inhibition with 4-OH androstendione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
86. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multi center multinational study
87. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells